AVOS Life Sciences

Table of Contents - Multiple Sclerosis

Disease Etiology 12
Possible Causes of Multiple Sclerosis 12
Epidemiology & Patient Population Estimates 14
Theoretical Patient Population 14
Risk, Pre-Disposing Factors 14
Diagnosis Rates 16
Addressable Patient Population 16
Treated Patient Population 16
U.S. Multiple Sclerosis Market Models, 2005-2014E 17
Market Definitions 17
Forecasting Methodology 17
Market Revenue Forecasts 22
AVOS Physician Panel Results 23
Physician Diagnosis Pattern 23
Disease Progression and Symptoms 23
Physician Treatment Patterns 25
Mild-to-Moderate RRMS - First-Line Treatments 25
Mild-to-Moderate RRMS - Second-Line Treatments 26
Aggressive MS - First-Line Treatments 26
Aggressive MS - Second-Line and Last Resort Treatments 27
Patient Compliance 28
Key Factors of Non-Compliance 28
Physician Product Selection Criteria 29
Physician Comments on Product Criteria 29
Physician Product Comparison and Ratings 30
Market Dynamics and Assessment 32
Leading Products 32
Market History 32
Current Market Environment 33
Future Market Environment 35
Generic Biologics 35
Introduction of Novel MS Therapies 36
Increases in the MS Population 39
Increased Awareness and Diagnosis 40
New Frontiers in R&D 40
Increased Regulatory Standards 40
Unmet Medical Needs in MS 41
Prospects for Future Therapies 42
Future Strategies for MS Therapies 42
Product Profiles: Inline and Select Pipeline 43
Avonex 44
U.S. Perspective 44
Worldwide Perspective 45
AVOS Physician Panel Discussions 45
Betaseron 46
U.S. Perspective 46
Worldwide Perspective 47
AVOS Physician Panel Discussions 47
Rebif 48
U.S. Perspective 48
Worldwide Perspective 49
AVOS Physician Panel Discussions 49
Copaxone 50
U.S. Perspective 50
Worldwide Perspective 51
AVOS Physician Panel Discussions 51
Tysabri 52
U.S. Perspective 52
Worldwide Perspective 54
AVOS Physician Panel Discussions 54
Novantrone 55
U.S. and Worldwide Perspective 55
Product History 55
AVOS Physician Panel Discussions 55
Extavia 56
U.S. Perspective 56
Worldwide Perspective 57
Cladribine 58
U.S. Perspective 58
Worldwide Perspective 59
FTY720 60
U.S. Perspective 60
Worldwide Perspective 61
Campath 62
U.S. Perspective 62
Worldwide Perspective 63
Laquinimod 64
U.S. Perspective 64
Worldwide Perspective 65
Teriflunomide 66
U.S. Perspective 66
Worldwide Perspective 67
AVOS Physician Panel Discussions 67
Drugs in Development 68
R&D Overview 68
Spectrum of Current MS Research 68
Conditions in the MS Therapeutic Market Inviting Scrutiny and Caution from the FDA 69
Assessment of R&D Success Rates 70
Products in the Pipeline 72
Phase III (13 agents) 72
Phase II (6 agents) 73
Appendix 74
Vital Statistics of Inline and Pipeline MS Agents 74
Cover

Production date: July 2008

Order

Print Copy - $5,000

Single Site license PDF - $7,000

Global License PDF - $9,995

Contact Information:

If you wish to see sample pages or to learn more about AVOS Therapeutic Market Reports, contact Mike Goodman
919-475-9695
reports@avoslifesciences.com